Establishment of a human fusion partner for making human T-T hybridomas which can grow in serum free medium.

Abstract

A new human fusion partner, ICLU-T was established for making human T-T hybridomas. Some 6-thioguanine resistant (6-TGr) clones were separated from human T cell acute lymphocytic leukemia, PEER. The fastest growing clone of the 6-TGr cells was scaled up and was cultured in serum free medium. The clone that proliferated most quickly in the serum free medium was separated and named ICLU-T. When ICLU-T was fused with human peripheral blood lymphocytes by using only polyethylene glycol, the viability of fused cells was below 20% just after fusion and the fusion efficiency was 0.01-0.02 per 10(5) parent cells. Whereas, the combined use of 1% lecithin with polyethylene glycol increased the viability over 50% and the fusion efficiencies over 0.2 per 10(5) parent cells on the average. In a total of 34 clones of obtained hybridomas, there were 25 CD2 positive clones. CD4 positive or CD8 positive clones of the CD2 positive clones were 12 and 5 clones, respectively. Further, 4 clones of all hybridomas were CD19 positive, and one clone of these hybridomas was an Ig producer. These obtained hybridomas could proliferate in serum free medium.

• Authors: H Kawahara, M Maeda-Yamamoto, K Hakamata
• Journal: Human antibodies (Hum Antibodies) Vol. 9 Issue 2 Pg. 83-7 ( 1999) ISSN: 1093-2607 [Print] Netherlands
• PMID: 10405828 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Culture Media, Serum-Free
• Phosphatidylcholines
• Polyethylene Glycols

Topics

• Cell Division
• Cell Fusion
• Cell Line
• Culture Media, Serum-Free
• Humans
• Hybridomas (physiology)
• Phosphatidylcholines (pharmacology)
• Polyethylene Glycols (pharmacology)
• T-Lymphocytes (physiology)